 | Up a level |
Journal Article
Hoyer, K., Hablesreiter, R., Inoue, Y., Yoshida, K., Briest, F., Christen, F., Kakiuchi, N., Yoshizato, T., Shiozawa, Y., Shiraishi, Y., Striefler, J. K., Bischoff, S., Lohneis, P., Putter, H., Blau, O., Keilholz, U., Bullinger, L., Pelzer, U., Hummel, M., Riess, H., Ogawa, S., Sinn, M. and Damm, F. (2021). A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial. EBioMedicine, 66. AMSTERDAM: ELSEVIER. ISSN 2352-3964
Juhling, A., Sinn, M., Klein, F., Bischoff, S., Striefler, J. K., Pelzer, U., Oettle, H., Riess, H., Denkert, C., Blaker, H. and Lohneis, P. (2018). Tumor buds determine prognosis in resected pancreatic ductal adenocarcinoma. Oncol. Res. Treat., 41. S. 191 - 192. BASEL: KARGER. ISSN 2296-5262
Sinn, M., Liersch, T., Riess, H., Gellert, K., Stuebs, P., Waldschmidt, D., Lammert, F., Maschmeyer, G., Bechstein, W., Bitzer, M., Denzlinger, C., Hofheinz, R., Lindig, U., Ghadimi, M., Hinke, A., Striefler, J. K., Pelzer, U., Bischoff, S., Bahra, M. and Oettle, H. (2020). CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine plus sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results. Eur. J. Cancer, 138. S. 172 - 182. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852